Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting® 2017

Organovo today presented new preclinical data showing extended survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into diseased animal models.
a year ago

SAN DIEGO, Oct. 20, 2017 (GLOBE NEWSWIRE)

Organovo today presented new preclinical data showing extended survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into diseased animal models. This data will be presented at The Liver Meeting 2017 (American Association For The Study of Liver Diseases or “AASLD”) by Vaidehi Joshi, Scientist I, Therapeutics, at Organovo.

Organovo previously implanted its 3D bioprinted human liver tissue patches onto the livers of healthy NOD/SCID mice, and is now presenting additional data from promising early studies in an established model for alpha-one-antitrypsin deficiency (“A1AT”). The tissue was composed of human hepatocytes and select non-parenchymal cells. Serum and histopathologic evaluation of the implanted therapeutic tissue showed engraftment, retention and a high degree of disease clearing through 125 days post-implantation, a significant increase in duration from the Company’s first preclinical studies, which demonstrated functionality through 28 days. These results demonstrate a significant increase in the reported duration of implanted human hepatocyte synthetic function, demonstrating sustained presence of key human liver proteins such as albumin and A1AT in the animal bloodstream. Importantly, pathologic evaluation of diseased animals receiving implanted bioprinted liver tissues suggests an approximately 75 percent reduction in the pathologic hallmarks of the disease in treated animals versus non-treated control animals in the region of implant.

“With tens of thousands of patients being treated for inborn errors of metabolism (“IEMs”) in the U.S., and an annual cost per patient that exceeds $250,000 for drug therapy alone, Organovo continues to advance a novel therapeutic solution for direct surgical implantation,” said Eric David, M.D., J.D., chief strategy officer and executive vice president of preclinical development, Organovo. “Our preclinical data continues to show robust engraftment and durability of the liver tissue and strong early evidence of successfully impacting the disease state in animal models. Taken together, these data support continued preclinical development of Organovo’s 3D bioprinted liver tissue for therapeutic use.”

“The data show that the approach of delivering a 3D bioprinted tissue patch directly to the liver offers great promise in solving the engraftment and integration issues that have held back many cell and gene therapy attempts at these diseases,” said Dr. David Brenner, vice chancellor of Health Sciences and dean of the School of Medicine at UC San Diego, who is also an advisor to Organovo. “We’re encouraged by these solid early results, and are eager to see this work advance to the next stages. UC San Diego’s ability to leverage translational research to understand and redress disease progression is one of the many reasons we’re ideally suited for this kind of collaboration.”

Focusing first on pediatric inborn errors of metabolism, Organovo intends to submit an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its therapeutic liver tissue in calendar-year 2020. In the next 12 months, the Company expects to optimize its final liver tissue design and continue pre-GLP studies, including efficacy, safety and dosing studies in small animal disease models for IEMs. Organovo is also seeking orphan designation in the U.S. and will partner with contract research organizations (“CROs”) to define and scope IND enabling studies. 

Source: Organovo

Illustration Photo: Bioprinted vascular conduit after 28 days of bioreactor conditioning, highlighting the layered architecture and deposition of extracellular matrix (blue color). Image is Masson’s Trichrome (20x). (Credit: Organovo)

Comments

No comments to display.

Related posts

EU Call for Proposals: Multi-use of the marine space, offshore and near-shore: pilot demonstrators

Activities shall develop pilots by involving industrial actors and by integrating the available knowledge, technologies and facilities, in particular capitalising on the results of EU and national projects for the development of multi-use platforms or co-location of different activities in a marine space, and relevant support offshore vessels and autonomous vehicles.
Application Deadline in 3 days
4 hours ago

EU Call for Proposals: The Future of Seas and Oceans Flagship Initiative

Proposals shall address one of the following sub-topics: blue cloud services, or ocean observations and forecasting, or technologies for observations (in 2020). Actions shall demonstrate integration, capacity and (scientific, economic etc) potential.
Application Deadline in 3 days
5 hours ago

EU's Call for Proposals: Modelling international trade in agri-food products

Trade modelling has a long-standing tradition but some issues are notoriously difficult to assess and include in the existing simulation models.
Application Deadline in 3 days

EU Call for Proposals: Circular bio-based business models for rural communities

Based on an established agro-food system, proposals shall consider a variety of additional bio-based processes and end products that could be integrated into the system, and that are viable on a small scale (farm to rural community level).
Application Deadline in 3 days
5 hours ago

The Infant Formula Testing Market is expected grow at a CAGR of 6.9% to reach revenue of $20.26billion by 2023.

Infant formula is one of the emerging markets in food and beverage industry. It is basically used for the infants whose age is below 12 months (preferably).

UNICEF Innovation Fund's Call for Applications: Data science, machine learning, artificial intelligence or similar technology solutions

The UNICEF Innovation Fund is looking to make up to 100K equity-free investments to provide early stage (seed) finance to for-profit technology start-ups that have the potential to benefit humanity. If you’ve got a start-up registered in one of UNICEF’s programme countries and have a working, open source prototype (or you are willing to make it open-source) showing promising results, the UNICEF Innovation Fund is looking for you.
Application Deadline in a month

Etisalat Digital accelerates adoption of Artificial Intelligence and Blockchain in the United Arab Emirates

Etisalat Digital selects four disruptive companies to join Future Now scaleup programme after Dubai Future Accelerators collaboration.

European Venture Investment Reaches All-Time High

Europe's venture capital investment eclipsed €20 billion for the first time ever, according to PitchBook's 4Q 2018 European Venture Report. Despite the 25.9% drop in deal volume year-over-year (YoY), swelling deal sizes and increased interest from nontraditional investors helped drive deal value to the high-water mark.

The African Union Ten Years Aquaculture Action Plan for Africa 2016 - 2025

The prospects for Africa’s aquaculture are enormous. They are defned by the continent’s vast aquatic resources, land mass and climate that are suitable for the production of an array fsh species and essential inputs such as ingredients for feed. Of added advantage, is the fact that most of the world’s important tropical and sub-tropical aquaculture species are native to Africa.

Singapore-based SEEDS Capital appoints seven partners to co-invest in agrifood tech startups

SEEDS Capital, the investment arm of Enterprise Singapore, has appointed seven co-investment partners under Startup SG Equity. This will catalyse more than S$90 million worth of investments to develop Singapore-based startups in the Agrifood tech sector. This was announced by Senior Minister of State for Trade and Industry, Dr Koh Poh Koon, at the opening of Indoor Ag-Con Asia.